ABSTRACT
The dominance of the COVID-19 Delta variant has renewed questions about the impact of K12 school policies, including the role of masks, on disease burden.1 A recent study showed masks and testing could reduce infections in students, but failed to address the impact on the community,2 while another showed masking is critical to slow disease spread in communities, but did not consider school openings under Delta.3 We project the impact of school-masking on the community, which can inform policy decisions, and support healthcare system planning. Our findings indicate that the implementation of masking policies in school settings can reduce additional infections post-school opening by 23-36% for fully-open schools, with an additional 11-13% reduction for hybrid schooling, depending on mask quality and fit. Masking policies and hybrid schooling can also reduce peak hospitalization need by 71% and result in the fewest additional deaths post-school opening. We show that given the current vaccination rates within the community, the best option for children and the general population is to employ consistent high-quality masking, and use social distancing where possible.
Competing Interest Statement
Dr. Patel reported receiving grants from the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health (NIH) and from the Council of State and Territorial Epidemiologists (CSTE) during the conduct of the study. Mr. Rosenstrom reported receiving support from the Centers for Disease Control and Prevention (CDC), the Council of State and Territorial Epidemiologists (CSTE), and NCATS/NIH during the conduct of the study. Ms. Mele reported receiving support from the CDC, CSTE, and NCATS/NIH during the conduct of the study. Dr. Ivy reported receiving grants from the CDC, CSTE, NCATS, and NC State University during the conduct of the study. Dr. Mayorga reported receiving grants from the NCATS/NIH, CSTE, CDC, and NC State University during the conduct of the study. Dr. Swann reported receiving grants from NCATS/NIH, CDC, CSTE, and NC State University during the conduct of the study. No other disclosures were reported.
Clinical Trial
This study does not meet the definition of a clinical trial.
Funding Statement
This research was supported by grant UL1TR002489 from the NCATS/NIH and Cooperative Agreement NU38OT000297 from the CSTE and the CDC.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This manuscript uses publicly available data from the US Census, published estimates of disease parameters, and data obtained from North Carolina department of Health on age-based vaccination rates. The Institutional Review Board of NC State reviewed the project and determined that no IRB approval would be needed since identifiers are not included with the dataset and individuals cannot be directly or indirectly identified.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
This manuscript uses publicly available data from the US Census, published estimates of disease parameters, data obtained from the North Carolina Department of Health Data Dashboard, and estimates obtained from the Covid-19 Case Surveillance Restricted Access Detailed Data.